myome | atlas™ CURATED SCREEN™

Provider Guide

Understanding Test Results: Atlas Curated Screen™

This guide provides step-by-step guidance for interpreting patient results from the Curated Screen* test.

Results Overview

Atlas Curated Screen identifies actionable pathogenic and likely pathogenic variants in a curated set of genes linked to 40+ health conditions, including hereditary cancers and cardiac diseases.

To support clinical clarity and action, variants of uncertain significance (VUS) are not reported.

Scan for more test information

Technical Overview

Product Overview

Report Walkthrough

POSITIVE RESULT

A pathogenic variant was identified in the PALB2 gene.

1 GENE	RESULT	2 VARIANT	3 ZYGOSITY
PALB2	Pathogenic	NM_024675.3:c.2167_2168del	Heterozygous

4 CLINICAL INFORMATION

This testing found that you have a change in a gene called *PALB2*, which is known to increase the risk of developing certain cancers, primarily breast, ovarian, and pancreatic.

Women with a pathogenic variant in *PALB2* have a 33-58% chance of developing breast cancer (PMID 25099575, 31841383), a 5% chance of developing ovarian cancer and a 1-4% chance of developing pancreatic cancer by age 80. Men have a 2-5% chance of developing pancreatic cancer and a 1% chance of developing male breast cancer by age 80 (PMID 31841383).

Variants in the *PALB2* gene associated with cancer predisposition are inherited in an autosomal dominant manner. This means that there is an increased risk for relatives to also have this variant. *PALB2* is also associated with a rare autosomal recessive condition called Fanconi anemia. Individuals need to inherit two variants, one from each parent, to have Fanconi anemia. This result is consistent with being a carrier for Fanconi anemia.

1 GENE INFORMATION
The gene in which the variant was identified.

2 VARIANT
The specific genetic variant detected.

3 ZYGOSITY
How many copies of the variant were detected.

4 CLINICAL INFORMATION
Brief overview of the disease and risks associated with the genetic variant detected.

NEGATIVE RESULT

1 No pathogenic variants were found.

NEXT STEPS

- These results should be interpreted in the context of clinical findings, family history, and other laboratory data. All genetic tests have limitations. See limitations and other information about this test on the following pages.
- **Next step: contact your healthcare provider.** Whether or not you develop a disease is not determined by your genetics alone. It is still recommended you share and discuss your results with a healthcare provider so they can help you make informed medical decisions.
- **What do my results mean for my family members?** Even though your test results were negative, your family members have their own unique genetic makeup. Genetic testing may still be indicated for your family members to help them understand their chance of developing a genetic disease.
- **Resources to help.** Genetic counseling can help address any questions you have about your results or your personal or family medical history.

1 RESULT SUMMARY
A negative result does not eliminate the risk of the patient developing any of the associated conditions. The test may not cover all genes or genetic variants associated with a particular condition. A patient's family history, lifestyle, and environment should also be considered.

*Formerly offered as "Single-Gene Risk" under MyOme Proactive Health

myome | atlas™ CURATED SCREEN™

Provider Guide

Next Steps[1-4]

Screening

Depending on the identified risk, guidelines may recommend increased screening frequency and/or specific screening methods. Even with a negative result, personal or family history of a condition included in the test may still warrant increased clinical screening or diagnostic genetic testing.

Family testing

A positive result can be shared with family members who may benefit from genetic testing to guide screening and care. A negative result does not eliminate unique risks for other relatives, so they may still benefit from genetic risk assessment.

Interventions

Depending on the health condition risk(s) identified, clinical guidelines may recommend lifestyle modifications or medications aimed at reducing risk.

Additional Support

Clinician-Clinician Consultation*

Schedule a clinician-to-clinician consultation to review results and management considerations is included with every report.

Patient Genetic Counseling*

Genetic counseling is included in every report to help patients understand their results and what they mean for their care.

Provider Resource Hub

Additional guides, FAQs, and educational resources are available on our website.

*These optional resources are offered by our third-party provider, DNAvisit.

We're Here to Help

For additional interpretation support, fill out our Contact Us form or reach out directly to support@myome.com to set up a consultation.

1. Antoniou et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014; 371(371):497-506. PMID: 25099575.
2. Yang et al. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. 2020; 38(38):674-685. PMID: 31841383.
3. Catucci et al. PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo. Genet Med. 2014; 16(16):688-94. PMID: 24556926.
4. Zhou et al. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing. Cancer. 2020; 126(126):3202-3208. PMID: 32339256.